Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals

Brian Grunau(Island Health), Martin A. Prusinkiewicz(University of British Columbia), Michael Asamoah-Boaheng(Memorial University of Newfoundland), Liam Golding(University of British Columbia), Pascal M. Lavoie(University of British Columbia), Martin Petric(University of British Columbia), Paul N. Levett(University of British Columbia), Scott Haig(Island Health), Vilte Barakauskas(University of British Columbia), Mohammad Ehsanul Karim(St. Paul's Hospital), Agatha N. Jassem(University of British Columbia), Steven J. Drews(University of Alberta), Sadaf Sediqi(University of British Columbia), David A. Goldfarb(University of British Columbia)
Microbiology Spectrum
September 19, 2022
10.1128/spectrum.01315-22
Cited by 37Open Access
Full Text

Abstract

Live viral neutralizing antibody titers are an accepted measure of immunity; however, testing procedures are labor-intensive. COVID-19 antibody and angiotensin converting enzyme-2 (ACE-2) levels have been used as surrogates to live viral neutralizing antibody titers; however, validity among vaccinated individuals is unclear. Using samples from 120 two-dose mRNA vaccinees without previous COVID-19, we found that live viral neutralization was correlated with COVID-19 antibody and ACE2 binding levels. When grouping samples by the time interval between vaccination and sample blood collection, samples collected over 158 days after the first vaccine and over 71 days from the second vaccine demonstrated stronger correlation between live viral neutralization titers and both antibody and ACE2 levels, in comparison to those collected earlier.

Related Papers

No related papers found

Powered by citation graph analysis